Patients who entered the second extension study received either calcium only or ZOL 4 mg.
The patients in that study received either enoximone (bolus dose of 0.5 mg/kg followed by an infusion of 2.5 μg/kg per min) or normal saline.
Since very few patients in this study received either adjuvant (<3%) or neoadjuvant therapy (0%), the effect of therapy in colon and rectal cancer could not be examined.
No patients in the current study received either glucocorticoid or disease-modifying anti-rheumatic drug therapy prior to recruitment and the collection of baseline urine or blood samples.
Differences attributable to other anti-diabetic agents cannot be evaluated, as participants in the rosiglitazone study received both metformin and a sulphonylurea [ 19] whereas participants in the pioglitazone study received either one or the other [ 20].
Our results do not support this observation given that patients in our study received either 80 mg m−2 weekly or 180 mg m−2 biweekly of irinotecan and the association with toxicity was strong.
46% (29/62) of patients with AKI had AKIN stage 3 and were eligible for dialysis or ICU admission, but none of the patients in the study received either management option.
However, patients in that study received either low molecular weight heparin or unfractionated heparin as perioperative anticoagulant therapy, starting 2 h before surgery and continued until postoperative day 7.
For their primary infant schedule, the participants in this study received either a DTwP-Hib (ACT-HIB DTP, Pasteur Merieux MSD Ltd ,Maidenhead, UK) or DTaP-Hib (Infanrix-Hib, GlaxoSmithKline, Middlesex, UK).
Patients in this study received either nivolumab and ipilimumab every 3 weeks for 4 doses, followed by nivolumab alone every 3 weeks for 4 doses (concurrent regimen) or nivolumab every 2 weeks for up to 48 doses if they had been treated with ipilimumab before (sequenced regimen).
